Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908732 | Leukemia Research | 2015 | 8 Pages |
Abstract
In summary, we show ganetespib to have high activity in primary AMLs as a monotherapy and a synergistic relationship with cytarabine when combined. The combination of cytotoxic cell death, suppression of cytoprotective/drug resistance mechanisms such as AKT and reduced clinical toxicity compared to other HSP90 inhibitors provide strong rationale for the clinical assessment of ganetespib in AML.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Lazenby, R. Hills, A.K. Burnett, J. Zabkiewicz,